TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical evidence of pulmonary hypertension (PH) requiring INO therapy as prescribed by the attending physician.~2. Indwelling arterial catheter.~3. Signed informed consent~Exclusion Criteria:~1. Clinically unstable circulatory condition requiring epinephrine \> 0.1 mcg/kg/min or levophed, or already meeting treatment failure criteria (see section 5.3 below)~2. Known hypersensitivity to prostacyclin compounds~3. Patients receiving sildenafil or bosentan~4. Refusal by the attending physician

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2: Inhaled Iloprost continuous (Type: EXPERIMENTAL): Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy.
- Phase 1: Inhaled Iloprost 3 doses (Type: EXPERIMENTAL): Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: REV 002 Observational Study of the ReVENT Sleep Apnea System: Minimally Invasive Treatment for Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with Obstructive Sleep Apnea due to primary tongue base closure.~* AHI ≥ 10 and AHI ≤ 40 (at least 90% of apneas and hypopneas must be obstructive).~* BMI ≤ 32.~* Confirmation of tongue base closure as the primary source of obstruction with Drug Induced Sleep Endoscopy (DISE).~Exclusion Criteria:~* Patient with prior tongue-base surgery~* Uvulopalatopharyngoplasty, soft palate surgery, tonsillectomy or minimally invasive RF ablation of the tongue within the last six (6) months.~* History of mandibular and/or hyoid advancement to treat OSA.~* Any contraindications as listed in the approved Instructions for Use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ReVENT implanted group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Accuracy of Microvessel Ultrasound Imaging for Detecting Extent of Disease in Patients With Angiosarcoma of the Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy~* Twenty one years of age or older~Exclusion Criteria:~* Unwilling to consent to microvessel ultrasound imaging~* Younger than 21 years of age

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (microvessel ultrasound imaging) (Type: None): Patients undergo microvessel ultrasound imaging on study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cirrhosis of any aetiology~* Diuretic resistant ascites defined as i) an inability to mobilise ascites (minimal or no weight loss) despite administration with the maximum tolerable doses of oral diuretics or a daily dose of spironolactone 400 mg and re-accumulation of fluid after therapeutic paracentesis within two weeks or ii) diuretic-related complications including (but not limited to) azotemia, hepatic encephalopathy, or progressive electrolyte imbalances~* Able to read and understand Danish~* Signed and dated informed consent form~* Willing to comply with all study procedures and be available for the duration of the study~* Male or female of any age~* Age at least 18 years~* Expected survival at least three months.~Exclusion Criteria:~* Participants eligible and listed for TIPS~* Serum creatinine levels above 135 umol/L~* Overt hepatic encephalopathy in the two weeks before randomization~* Ascites due to other causes than cirrhosis such as: malignant disease, congestive heart failure, end-stage renal disease, pancreatitis, or Budd-Chiari (hepatic vein thrombosis), or chylous ascites~* Ongoing intra-abdominal infection (peritonitis) or active systemic or local infections, such as urinary tract infection or pneumonia~* Participation in a clinical study that may interfere with participation in this study;~* Evidence of extensive ascites loculation~* Coagulopathy~* Variceal bleeding within two weeks before randomisation~* Intraabdominal surgery within four months before randomisation~* Spontaneous bacterial peritonitis (neutrophil count\>250/µl within 24 hours of randomization)~* Patients with an increased risk of procedure related complications as judged by the primary healthcare provider

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PleurX (Type: EXPERIMENTAL): The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
- Large Volume Paracentesis (Type: ACTIVE_COMPARATOR): Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Hemodialysis Catheter Use in Prevalent Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Dialyzing with a CVC~* Receiving hemodialysis three times weekly for \> 3 months~Exclusion Criteria:~* Awaiting peritoneal dialysis catheter insertion~* Scheduled living donor transplant~* Transient patients from out of province~* Expected transfer to satellite dialysis unit within 6 months~* Surgical plan for AVF (i.e. scheduled date)~* Documented lack of suitable vasculature for AVF~* Refusing AVF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protocolized approach (Type: EXPERIMENTAL): Protocolized approach to convert catheter to arteriovenous fistula
- Current Care Model (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Oscillations Underlying Human Cognitive and Affective Processing Using Intracranial EEG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. History of medically intractable epilepsy~2. Capable of giving informed consent~3. Aged 18 - 80 years, either sex~Exclusion Criteria:~1. Major systemic illness~2. Severe cognitive impairment defined as mini-mental state examination of less than 20~3. Severe psychiatric illness~4. Excessive use of alcohol or other substances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive and Emotion Processing Tasks (Type: EXPERIMENTAL): As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Performance of IGRAs for TB Infection Diagnosis in Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 75 years~* Consent signed~* hospitalized patient with start treatment of Tuberculosis disease~* French social right~Exclusion Criteria:~* Tuberculosis disease treatment since 7 days~* No 3 months follow-up possible~* Immunosuppression

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active TB-infected patients (Type: None): TB-infected patients with bacteriological and histological evidences
- Non active TB-infected patients (already met TB) (Type: None): some of elders have already met M tuberculosis before active antibiotherapy exists
- Non active TB-infected patients (other diagnosis) (Type: None): same symptoms than two others groups but an other diagnosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients:~* age ≥18 years~* Karnofsky Performance Score ≥ 50 %~* histologically confirmed, previously untreated GBM~* radiochemotherapy according to Stupp et al \[1\] is planned (ideally, treatment start can be scheduled on a Monday)~* no cardiovascular or neurological contraindications for 6MWT and/or a history of instable angina pectoris or NYHA grade II or greater congestive heart failure (according to the Thoracic Society recommendations \[2\])~* willing and able to comply with the protocol as judged by the investigator~* signed informed consent~Partners:~* age ≥18 years~* willing and able to comply with the protocol as judged by the investigator~* spouse or partner living in the same home as the patient or closest contact as named by the patient (1-2h 5 days a week)~* signed informed consent~Exclusion Criteria:~Patients:~* Patients who have any other disease, either metabolic or psychological, or who have any evidence on clinical examination or special investigations (including laboratory findings) which give reasonable suspicion of a condition that interferes with the adequate measurement of the stress axis (e.g. chronic use of corticosteroids ≥ 3 months before study entry for disease other than glioblastoma, (dexamethasone use in the context of glioblastoma is allowed)~* Severe, medically treated psychiatric disorder prior to the diagnosis of glioblastoma~* Participation in a study with investigational drugs~* Severe asthma or known allergy against tetracosactide (Synacthen®)~* Pregnancy or breast feeding~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurologic deficits that interfere with the planned walking tests, dementia or confusional state~Partners:~* Individuals who have any disease, either metabolic or psychological, that interferes with the adequate measurement of the stress axis (e.g. chronic use of corticosteroids (≥ 3 months), psychiatric disorders)~* Pregnancy or breast feeding~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- stress (Type: None): patient with glioblastoma diagnosis and partners

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Research of Alzheimer's Disease Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* older adults with a diagnosis of possible or probable Alzheimer's disease~* planning to initiate treatment with a cholinesterase inhibitor~* planning to continue care in the memory care practice~* participation by a family caregiver willing to complete the study outcome assessments~* access to a telephone~* ability to understand English-Language survey instruments~Exclusion Criteria:~• prior serious adverse event from the study medications

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): See intervention note.
- Galantamine (Type: EXPERIMENTAL): See intervention note.
- Rivastigmine (Type: EXPERIMENTAL): See intervention note.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age and older~* Undergoing anterior cervical discectomy and fusion (ACDF) for radiculopathy or myelopathy~* No known allergies or sensitivities to steroid or non-steroidal medications~Exclusion Criteria:~* Procedure is being done for revision, trauma, infection or tumor~* Patients with known diagnosed metabolic diseases (diabetes, pancreatitis, gout, electrolyte imbalances, hypertension, hematological abnormalities including gastrointestinal bleeding...)~* Patients with known kidney disease or a creatinine level above the upper limit of normal \>1.27

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): no steroid or non steroidal anti-inflammatory
- Ketorolac (Type: ACTIVE_COMPARATOR): one time dose of 30mg of IV Ketorolac at time of closure
- dexamethasone (Type: ACTIVE_COMPARATOR): one time dose of 10mg of IV dexamethasone at the time of closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: Study Comparing Midazolam and Propofol With Midazolam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 20~* ECOG ≥ 2~* patient who consents to enroll the trial~Exclusion Criteria:~* age \< 20~* pregnant or lactating women~* American Society of Anesthesiology (ASA) physical status class V~* chronic pulmonary disease~* history of allergic to propofol~* history of complication of sedation endoscope~* liver failure or hepatic encephalopathy~* who didn't consented to enroll the trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- conventional sedation group (Type: ACTIVE_COMPARATOR): midazolam
- BPS group (Type: EXPERIMENTAL): midazolam plus propofol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stellate Ganglion Block in Head and Neck Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking patients who are greater than eighteen years of age with a known diagnosis of head and neck cancer and are planned to undergo surgery with unilateral neck dissection will be eligible for this study~Exclusion Criteria:~* Patients with a history of preoperative narcotic use for conditions unrelated to their head and neck cancer will be excluded.~* Patients younger than eighteen years of age, patients with a history of vocal cord paralysis on the non-surgical side, patients with a history of severe difficulty swallowing, and pregnant patients will be excluded from this study.~* Patients with a history of abnormal heart rhythm will be considered to have a relative contraindication and will require clearance by the consultant anesthesiologist prior to participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
- Control (Type: NO_INTERVENTION): Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis;~* WhO PFS \<= 2~* Tumours which do enhance on pre-operative imaging.~* Post-operative enough visible residual tumour on PET or status after biopsy only~* Age \>18 years~* Availability of deep fresh frozen tissue for molecular biologic evaluation - if possible~* Patient able to tolerate full course of conventional RT and follow serial scanning~* No previous radiotherapy to the head and neck and brain area.~* Prior neurosurgery within 6 weeks of treatment~* No previous chemotherapy before treatment of the glioma. Standard radiochemotherapy with temozolomide is not excluded~* No prior or concurrent medical condition which would make treatment difficult to complete. Medication with steroids is allowed.~* No incapacitated patients.~Exclusion Criteria:~* Not histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis;~* WhO PFS \> 2~* No tumours which do enhance on pre-operative imaging.~* Post-operative not enough visible residual tumor on PET or status after biopsy only~* Age \<18 years~* No availability of deep fresh frozen tissue for molecular biologic evaluation~* Patient not able to tolerate full course of conventional RT and follow serial scanning~* Previous radiotherapy to the head and neck and brain area.~* Prior neurosurgery not within 6 weeks of treatment~* Previous chemotherapy before treatment of the glioma.~* Prior or concurrent medical condition which would make treatment difficult to complete.~* Incapacitated patients.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (Type: None): Patients with a primary glioblastoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues